Healthcare provider profile · identity verified

Rory Ratzlaff, MD

Family Practice · WEST FARGO, ND · NPI 1679068035

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	261	87
Lisinopril	Lisinopril	178	58
Rosuvastatin Calcium	Rosuvastatin Calcium	161	53
Amlodipine Besylate	Amlodipine Besylate	156	56
Omeprazole	Omeprazole	110	35
Gabapentin	Gabapentin	105	35
Levothyroxine Sodium	Levothyroxine Sodium	103	27
Losartan Potassium	Losartan Potassium	100	32
Metoprolol Succinate	Metoprolol Succinate	93	33
Simvastatin	Simvastatin	88	25
Tamsulosin Hcl	Tamsulosin Hcl	88	29
Furosemide	Furosemide	76	23
Metformin Hcl Er	Metformin Hcl	62	17
Metformin Hcl	Metformin Hcl	61	20
Hydrochlorothiazide	Hydrochlorothiazide	59	23
Sertraline Hcl	Sertraline Hcl	59	18
Fluoxetine Hcl	Fluoxetine Hcl	54	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	15
Eliquis	Apixaban	52	18
Metoprolol Tartrate	Metoprolol Tartrate	52	16
Finasteride	Finasteride	50	18
Montelukast Sodium	Montelukast Sodium	45	16
Pantoprazole Sodium	Pantoprazole Sodium	44	13
Trazodone Hcl	Trazodone Hcl	44	14
Pravastatin Sodium	Pravastatin Sodium	43	suppressed
Allopurinol	Allopurinol	42	14
Carvedilol	Carvedilol	40	suppressed
Bupropion Xl	Bupropion Hcl	37	suppressed
Famotidine	Famotidine	37	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	14
Albuterol Sulfate Hfa	Albuterol Sulfate	36	17
Donepezil Hcl	Donepezil Hcl	35	suppressed
Duloxetine Hcl	Duloxetine Hcl	33	13
Ropinirole Hcl	Ropinirole Hcl	32	suppressed
Celecoxib	Celecoxib	31	suppressed
Spironolactone	Spironolactone	31	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	11
Tramadol Hcl	Tramadol Hcl	27	12
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Jardiance	Empagliflozin	25	suppressed
Ozempic	Semaglutide	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Prednisone	Prednisone	20	15
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Digoxin	Digoxin	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Potassium Chloride	Potassium Chloride	19	11
Warfarin Sodium	Warfarin Sodium	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Meloxicam	Meloxicam	17	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Atenolol	Atenolol	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Topiramate	Topiramate	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Memantine Hcl Er	Memantine Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error